FDA investigates Zolgensma cancer risk as new tumor cases surface

· Health · United States

The FDA said Friday it is investigating a "serious risk" of cancer linked to Novartis' Zolgensma, the gene therapy for spinal muscular atrophy. The agency's action follows Novartis' disclosure of additional tumor cases in children who received the treatment. According to STAT, Novartis has disclosed seven previously unreported cases of tumors in children who received Zolgensma, and the new cases indicate that AAV gene therapies may carry tumor risks — a concern that extends beyond this one product to gene therapy researchers generally. Zolgensma is a one-time infusion built on an AAV vector, the most widely used delivery tool in gene therapy. The investigation puts the treatment's safety profile under regulatory scrutiny and raises questions for patients and for the broader AAV-based pipeline.

Why it matters：Zolgensma is among the highest-profile gene therapies, and a regulatory finding of cancer risk would affect the entire AAV delivery platform that much of the gene therapy field depends on.

Key points

  • The FDA called the cancer link a "serious risk" and opened the investigation on Friday.
  • Novartis disclosed seven previously unreported pediatric tumor cases, per STAT.
  • The concern centers on AAV vectors, the most common gene therapy delivery tool.

Sources (original reporting)

More stories from this day